Outlines four key policy areas Congress can act on now to protect generic and biosimilar medicines and provide access and savings for patients.
“It is an honor to serve as AAM board chair, and I thank the board for the privilege,” said Bob Hoffman.
Call for passage of Biosimilar Red Tape Elimination Act.
By John Murphy III, president and CEO of the Association for Accessible Medicines
Cuts red tape, brings patient faster access to lower-cost medicines.
FDA Commissioner Makary joined AAM’s GRx+Biosims 2025 conference today.
Generic pharmaceutical trade group steps in to protect patient access to affordable generic drugs.
AAM President John Murphy III noted that prices for generic and biosimilar medicines keep falling, yet no biosimilar for Enbrel is available in the U.S.
The bipartisan, bicameral legislation was included in the 2024 year-end spending bill and reintroduced in this Congress.
The Association for Accessible Medicines states that lower-cost drugs saved $3.4 trillion over the past decade but warns that regulatory and pricing pressures threaten the market's long-term viability.
“We look forward to a collaborative partnership with Dr. Tidmarsh and the larger team at CDER to prioritize regulatory efficiency.”
The paper concludes that, although the negotiation program might reduce drug costs initially, it could threaten the long-term sustainability of the generics and biosimilars market, a key driver of lower prescription costs.
White paper analyzes problems and solutions to patent abuses.
39 Groups support the Biosimilar Red Tape Elimination Act.
Ratner will lead AAM’s government relations team across federal and state relations, advocacy, and alliances.
A Minnesota law was found by the district court and appeals court to regulate prices in other states unlawfully.
